Author: Sterling Parsons

Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting

–Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia-...


Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations

DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...


Precision BioSciences to Present at Upcoming Industry and Investor Conferences

DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,...


Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress

DURHAM, N.C., Aug. 14, 2019 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...


Elo Life Systems’ Mario G. Pennisi Awarded BIO Leadership and Legacy Award in Industrial Biotechnology and Agriculture at BIO World Congress

DURHAM, N.C. and BRISBANE, Australia, July 10, 2019 – Elo Life Systems Inc. (“Elo”), a wholly owned subsidiary of Precision BioSciences, Inc. (Nasdaq: DTIL) announced today that Mario G....


Precision BioSciences to Present at Upcoming Investor Conferences

DURHAM, North Carolina, USA, May 29, 2019 – Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary...


Elo Life Systems Announces a Collaboration With Ashland Subsidiary Avoca to Scale a Sustainable, Key Input for Fragrances

DURHAM, NORTH CAROLINA – February 25, 2019 – Elo Life Systems Inc. announced today a collaboration with Avoca LLC, a subsidiary of the specialty chemicals company Ashland, that is focused on...


Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors

DURHAM, North Carolina, USA, December 19, 2018 – Precision BioSciences, a genome editing company dedicated to improving life, announced today that industry veteran Shalini Sharp has joined the...


Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space

CAPE CANAVERAL, FL, USA, December 6th, 2018 – Precision BioSciences today announced that the world’s first genome editing experiment in space has been launched aboard a SpaceX Dragon cargo...


Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

DURHAM, North Carolina, USA, November 27, 2018 – Precision BioSciences and Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND)...


Elo Life Systems Launches Australian Subsidiary in Queensland

RESEARCH TRIANGLE PARK, North Carolina, USA and BRISBANE, Australia, November 5, 2018 – Elo Life Systems has opened a new Australian location at the Queensland University of Technology (QUT),...